Naveen Yarlagadda

Researcher

UAMS primary UA Little Rock

Also affiliated: Roswell Park Comprehensive Cancer Center (2012–2013); University of Arkansas Medical Center (2018–2020); Winthrop Rockefeller Foundation (2020–2022)

Faculty Researcher

6 h-index 21 pubs 416 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Naveen Yarlagadda's research focuses on multiple myeloma, particularly the clinical significance of minimal residual disease (MRD) negativity. His work investigates the implications of losing MRD negativity after achieving it and identifies persistent MRD as a high-risk disease feature in multiple myeloma patients. Yarlagadda also studies the impact of tandem autologous stem cell transplantation for patients with persistent MRD after an initial transplant. Additionally, his research includes analyzing hematological and infectious complications associated with CD38-targeting monoclonal antibody therapies in multiple myeloma through meta-analyses of randomized control trials. He also examines phenotypic markers and disease progression in monoclonal gammopathy of unknown significance using eight-color flow cytometry. Yarlagadda has a publication record of 21 papers with 398 citations and an h-index of 6. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Sravani Gundarlapalli, Guido Tricot, Erming Tian, and Sharmilan Thanendrarajan.

Metrics

h-index: 6
Publications: 21
Citations: 416

Selected Publications

Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

American Journal of Hematology 6 citations DOI OpenAlex
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021)

Leukemia Research 2 citations DOI OpenAlex
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)

American Journal of Hematology 5 citations DOI OpenAlex
Clinical characteristics of testicular extramedullary involvement in multiple myeloma (2020)

American Journal of Hematology 4 citations DOI OpenAlex
Treatment Strategies and Outcomes for Patients with Peripheral T-Cell Lymphoma and Its Subtypes (2020)

Blood DOI OpenAlex
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns (2020)

Blood Cancer Journal 39 citations DOI OpenAlex
Hemophagocytic lymphohistiocytosis in adults (2020)

Baylor University Medical Center Proceedings 9 citations DOI OpenAlex
Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma (2019)

Baylor University Medical Center Proceedings 2 citations DOI OpenAlex
Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit (2018)

Blood 1 citation DOI OpenAlex
The Mutational Landscape of Primary Plasma Cell Leukemia (2018)

Blood 2 citations DOI OpenAlex
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma (2018)

OncoTargets and Therapy 286 citations DOI OpenAlex
Characteristics, associations, and outcomes of hemophagocytic lymphohistiocytosis: Retrospective data over a period of 13 years from a university hospital. (2018)

Journal of Clinical Oncology DOI OpenAlex